Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Liabilities and Shareholders Equity (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $76.6 million as the latest value for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 47.02% year-over-year to $76.6 million; the TTM value through Dec 2025 reached $408.8 million, down 40.57%, while the annual FY2025 figure was $76.6 million, 47.02% down from the prior year.
  • Liabilities and Shareholders Equity hit $76.6 million in Q4 2025 for Kezar Life Sciences, down from $97.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $317.5 million in Q2 2022 and bottomed at $76.6 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $196.5 million, with a median of $189.5 million recorded in 2024.
  • Year-over-year, Liabilities and Shareholders Equity surged 132.85% in 2022 and then crashed 47.02% in 2025.
  • Kezar Life Sciences' Liabilities and Shareholders Equity stood at $217.9 million in 2021, then surged by 37.46% to $299.6 million in 2022, then fell by 26.15% to $221.2 million in 2023, then crashed by 34.6% to $144.7 million in 2024, then plummeted by 47.02% to $76.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $76.6 million, $97.7 million, and $109.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.